We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Zeynep Eroglu

Zeynep Eroglu MD

Department of Cutaneous Oncology, Moffitt Cancer Center; Assistant Professor, Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, Florida

Recent Contributions to PracticeUpdate:

  1. Atezolizumab, Vemurafenib, and Cobimetinib as First-Line Treatment for Unresectable Advanced BRAFV600 Mutation–Positive Melanoma
  2. Adjuvant Nivolumab Plus Ipilimumab or Nivolumab Monotherapy vs Placebo in Patients With Resected Stage IV Melanoma With No Evidence of Disease
  3. The EORTC-DeCOG Nomogram Adequately Predicts Outcomes of Patients With SLN+ Melanoma
  4. Management of Early Melanoma Recurrence Despite Adjuvant Anti–PD-1 Antibody Therapy
  5. ASCO 2020: Abstract Recommendations From Dr. Zeynep Eroglu for Melanoma
  6. Melanoma in the COVID-19 Era: Advanced Metastatic Setting
  7. Melanoma in the COVID-19 Era: Metastatic Cancers
  8. Melanoma in the COVID-19 Era: Adjuvant Therapy
  9. Survival of Patients With Advanced Metastatic Melanoma
  10. Incidence and Predictors of CNS Metastasis for Patients With AJCC 8th Edition Stage III Melanoma

Most Read This Week

Recently Updated